AR113799A1 - Derivados de alcoxiamino para tratar dolor y estados relacionados con dolor - Google Patents
Derivados de alcoxiamino para tratar dolor y estados relacionados con dolorInfo
- Publication number
- AR113799A1 AR113799A1 ARP180103121A ARP180103121A AR113799A1 AR 113799 A1 AR113799 A1 AR 113799A1 AR P180103121 A ARP180103121 A AR P180103121A AR P180103121 A ARP180103121 A AR P180103121A AR 113799 A1 AR113799 A1 AR 113799A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- unbranched
- branched
- hydrogen atom
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La presente se refiere a compuestos de fórmula (1) que muestran una gran afinidad y actividad hacia la subunidad a2d de canales de calcio activados por voltaje (VGCC), o actividad doble hacia subunidad a2d de canales de calcio activados por voltaje (VGCC) y el transportador de noradrenalina (NET). La presente también se refiere al procedimiento para la preparación de dichos compuestos así como a composiciones que los comprenden, y a su uso como medicamentos. Reivindicación 1: Compuesto de fórmula general (1), en la que: R¹ es un radical un radical alquilo C₁₋₆ ramificado o no ramificado o un haloalquilo C₁₋₆; R² es un arilo de 6 miembros opcionalmente sustituido con un átomo de halógeno, un radical alquilo C₁₋₆ ramificado o no ramificado, un radical alcoxilo C₁₋₆ ramificado o no ramificado, un radical haloalcoxilo C₁₋₆, un radical haloalquilo C₁₋₆ o un radical hidroxilo; o un heteroarilo de 5 ó 6 miembros que tiene al menos un heteroátomo seleccionado de N, O y S; n y m son independientemente 0 ó 1; Z¹ y Z² se seleccionan independientemente de un átomo de hidrógeno; un radical alquilo C₁₋₆ ramificado o no ramificado; un átomo de halógeno; un radical alcoxilo C₁₋₆ ramificado o no ramificado; un radical cicloalquilo C₃₋₆; un radical haloalquilo C₁₋₆; y un radical haloalcoxilo C₁₋₆; -W-R³ está en posición meta o para; W es -(CH₂)ₚ-; -C(O)-; o un enlace; p es 1 ó 2; R³ representa uno de los restos del grupo de fórmulas (2), en los que Y¹ e Y² son independientemente -CH₂- o -C(O)-; Y³ es -CHR⁷- o -C(O)-; Y⁴ es -CH- o -N-R⁶; R⁴ y R⁵ son independientemente un átomo de hidrógeno, un radical alquilo C₁₋₆ ramificado o no ramificado o un radical -(CH₂)q-NRR en donde q es 0 ó 1 y R y R son independientemente un átomo de hidrógeno o un radical alquilo C₁₋₆ ramificado o no ramificado; uno o dos de A, B y D representan -N- y los otros son -CH-; E representa -N- o -CH-; R⁶ es un átomo de hidrógeno; un radical alquilo C₁₋₆ ramificado o no ramificado; o un radical -C(O)-CH₂-NR⁶ᵃR⁶ᵇ, en donde R⁶ᵃ y R⁶ᵇ son independientemente un átomo de hidrógeno o un radical alquilo C₁₋₆ ramificado o no ramificado; R⁷ es un átomo de hidrógeno; o alternativamente, R⁶ y R⁷ pueden formar un grupo heterocicloalquilo de 5 ó 6 miembros; R⁸ es un átomo de hidrógeno, un radical alquilo C₁₋₆ ramificado o no ramificado; un átomo de halógeno; un radical alcoxilo C₁₋₆, ramificado o no ramificado; un radical hidroxilo; un radical haloalquilo C₁₋₆; o un radical -NR⁸ᵃR⁸ᵇ, en donde R⁸ᵃ y R⁸ᵇ son independientemente un átomo de hidrógeno o un radical alquilo C₁₋₆ ramificado o no ramificado; R⁹ es un radical alquilo C₁₋₆ ramificado o no ramificado; o un radical alcoxilo C₁₋₆ ramificado o no ramificado; o una sal farmacéuticamente aceptable, isómero, profármaco o solvato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382721 | 2017-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113799A1 true AR113799A1 (es) | 2020-06-10 |
Family
ID=60262875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103121A AR113799A1 (es) | 2017-10-27 | 2018-10-26 | Derivados de alcoxiamino para tratar dolor y estados relacionados con dolor |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11401270B2 (es) |
| EP (1) | EP3700890B1 (es) |
| JP (1) | JP2021500416A (es) |
| KR (1) | KR20200097694A (es) |
| CN (1) | CN111566091A (es) |
| AR (1) | AR113799A1 (es) |
| AU (1) | AU2018356556A1 (es) |
| BR (1) | BR112020008371A2 (es) |
| CA (1) | CA3084425A1 (es) |
| ES (1) | ES2905582T3 (es) |
| IL (1) | IL274254A (es) |
| MA (1) | MA50455A (es) |
| MX (1) | MX2020003575A (es) |
| PH (1) | PH12020550594A1 (es) |
| PT (1) | PT3700890T (es) |
| RU (1) | RU2020114523A (es) |
| SG (1) | SG11202003599UA (es) |
| TW (1) | TW201925179A (es) |
| WO (1) | WO2019081691A1 (es) |
| ZA (1) | ZA202002526B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220024408A (ko) * | 2019-06-06 | 2022-03-03 | 허치슨 메디파르마 리미티드 | 트리사이클릭 화합물 및 이의 용도 |
| AU2022215118A1 (en) * | 2021-01-29 | 2023-08-17 | 3Z Ehf | Compounds for use in the treatment of attention deficit hyperactivity disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3702755A1 (de) * | 1987-01-30 | 1988-08-11 | Hoechst Ag | 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung |
| US7294642B2 (en) * | 2002-09-06 | 2007-11-13 | Elan Pharmaceuticals, Inc. | 1,3-Diamino-2-hydroxypropane pro-drug derivatives |
| PE20050068A1 (es) * | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
| EP1776106B1 (en) * | 2004-06-22 | 2013-08-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives for modulation of calcium channels |
| JPWO2006051851A1 (ja) * | 2004-11-10 | 2008-05-29 | わかもと製薬株式会社 | ２，３，４，５−テトラヒドロ−１ｈ−１，５−ベンゾジアゼピン誘導体、及び、医薬組成物 |
| US20100267697A1 (en) * | 2006-12-11 | 2010-10-21 | Wyeth | Ion channel modulators |
| TW200914457A (en) * | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
| HUE051829T2 (hu) * | 2016-05-06 | 2021-03-29 | Esteve Pharmaceuticals Sa | Tetrahidro-pirimido-diazepin és tetrahidro-pirido-diazepin vegyületek fájdalom és fájdalommal kapcsolatos állapotok kezelésére |
| WO2019076904A1 (en) * | 2017-10-16 | 2019-04-25 | Esteve Pharmaceuticals, S.A. | PROPANAMINE DERIVATIVES FOR THE TREATMENT OF PAIN AND PAIN DISEASES ASSOCIATED WITH PAIN |
-
2018
- 2018-10-26 SG SG11202003599UA patent/SG11202003599UA/en unknown
- 2018-10-26 MX MX2020003575A patent/MX2020003575A/es unknown
- 2018-10-26 AR ARP180103121A patent/AR113799A1/es unknown
- 2018-10-26 EP EP18800058.2A patent/EP3700890B1/en active Active
- 2018-10-26 CA CA3084425A patent/CA3084425A1/en active Pending
- 2018-10-26 PT PT188000582T patent/PT3700890T/pt unknown
- 2018-10-26 CN CN201880069540.1A patent/CN111566091A/zh active Pending
- 2018-10-26 BR BR112020008371-2A patent/BR112020008371A2/pt not_active Application Discontinuation
- 2018-10-26 KR KR1020207015088A patent/KR20200097694A/ko unknown
- 2018-10-26 ES ES18800058T patent/ES2905582T3/es active Active
- 2018-10-26 TW TW107138004A patent/TW201925179A/zh unknown
- 2018-10-26 RU RU2020114523A patent/RU2020114523A/ru unknown
- 2018-10-26 AU AU2018356556A patent/AU2018356556A1/en not_active Abandoned
- 2018-10-26 MA MA050455A patent/MA50455A/fr unknown
- 2018-10-26 WO PCT/EP2018/079367 patent/WO2019081691A1/en unknown
- 2018-10-26 US US16/755,992 patent/US11401270B2/en active Active
- 2018-10-26 JP JP2020543717A patent/JP2021500416A/ja active Pending
-
2020
- 2020-04-24 PH PH12020550594A patent/PH12020550594A1/en unknown
- 2020-04-26 IL IL274254A patent/IL274254A/en unknown
- 2020-05-07 ZA ZA2020/02526A patent/ZA202002526B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111566091A (zh) | 2020-08-21 |
| IL274254A (en) | 2020-06-30 |
| US11401270B2 (en) | 2022-08-02 |
| MA50455A (fr) | 2021-06-02 |
| EP3700890B1 (en) | 2021-11-17 |
| KR20200097694A (ko) | 2020-08-19 |
| RU2020114523A (ru) | 2021-12-01 |
| WO2019081691A1 (en) | 2019-05-02 |
| PT3700890T (pt) | 2022-02-02 |
| US20200299297A1 (en) | 2020-09-24 |
| AU2018356556A1 (en) | 2020-05-07 |
| PH12020550594A1 (en) | 2021-02-15 |
| TW201925179A (zh) | 2019-07-01 |
| BR112020008371A2 (pt) | 2020-11-03 |
| CA3084425A1 (en) | 2019-05-02 |
| MX2020003575A (es) | 2020-07-22 |
| SG11202003599UA (en) | 2020-05-28 |
| ZA202002526B (en) | 2021-06-30 |
| ES2905582T3 (es) | 2022-04-11 |
| EP3700890A1 (en) | 2020-09-02 |
| JP2021500416A (ja) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR110088A1 (es) | Inhibidores de magl | |
| AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
| AR108156A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-cd123 | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR088810A1 (es) | Moduladores del receptor mas acoplado a la proteina g utiles en el tratamiento de trastornos cardiovasculares y composiciones farmaceuticas que los contienen | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR113799A1 (es) | Derivados de alcoxiamino para tratar dolor y estados relacionados con dolor | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR116905A1 (es) | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor | |
| AR090323A1 (es) | Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1 | |
| AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor | |
| AR105358A1 (es) | Derivados de pirimidina | |
| AR111282A1 (es) | Inhibidores de cdpk1 ii, composiciones y métodos relacionados con los mismos | |
| AR117989A1 (es) | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico |